Retina
International
Scientific
Newsletter
We provide integrated data on retinal disorders, proteins, and genetics
After 10 years we need to refurbish the page. Please, take our apologies for any inconvenience.
Dr. rer. medic. Markus Preising, Dipl.Biol.
Laboratory of Molecular Ophthalmology
Department of Opthalmology
Universitaetsklinikum Giessen and Marburg GmbH, Giessen Campus
Head: Prof. Dr. med. Birgit Lorenz
CNTF Nano-Device NT501 Goes Into Phase 2/3 Clinical Trial in RP and Phase 2 Clinical Trials in AMD
See Press Release by Neurotech
Three Groups succeed in Gene Therapy Trials!
The Gene Therapy Study on REP65 delivered by an Adeno-associated Virus 2 construct by a team from Moorfields Eye Hospital and University College, London has been reported to be successfully. Dr. Bainbridge reported the first results on their study at this years ARVO meeting and in the New England Journal of Medicine. In parallel Jean Bennett reported the results of their group at the same meeting. The studies were published in parallel in the New England Journal of Medicine.
A third group with Sam Jacobson and Bill Hauswirth has meanwhile publish ed their approach.
All three groups have been successful within the limitations of their setup. Several questions as to persistence of expression, concentration of virus particles etc. remain to be tested.
The success of three independent groups will encourage further trials an other early onset retinal degeneration genes soon.